United States · Investor

Lilly Ventures

Last cheque observed Oct 2025. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

Corporate VCQuiet

DebtGrowthSeedHealth CareHealth DiagnosticsImpact Investing

Cheques on record
0%of best year0cheques in 12 months, 28 on record
Since the last cheque380days00hrs00min00sec
Median round$45MRounds led0 of 28Exits4 from the portfolioMostly inUnited States, 93%
Pitch Lilly Ventures

Lilly Ventures highlights

  1. 01

    28 rounds on record

  2. 02

    Mostly Series B and Series D: 50% of its rounds

  3. 03

    4 exits from the portfolio

What they do

Type
Corporate VC (from a list, unverified)
Cheque size
Not stated
Stages
DebtGrowthSeedSeries A
Sectors
Health CareHealth DiagnosticsImpact Investing
Based in
Indianapolis, United States
Cold pitches
Not stated

The record

Every round we can evidence, newest first28 appearances

  1. 2025

    1 round

  2. Oct
    NewLimitUS · Ventureburn$45MWith 11 others
  3. 2013

    3 rounds

  4. Nov
    Aileron TherapeuticsSeries E · US · finsmes.com$30MWith 5 others
  5. Jun
    Protagonist TherapeuticsSeries B · AU · protagonist-inc.com$14MWith 2 others
  6. Jan
    Aileron TherapeuticsSeries D · US · finsmes.com$12MWith 5 others
  7. 2012

    3 rounds

  8. May
    Sutro BiopharmaSeries C · US · finance.yahoo.com$17MWith 4 others
  9. Mar
    ReceptosVenture · US$30MWith 5 others
  10. Mar
    HemaQuest PharmaceuticalsSeries B · US · hemaquest.com$13MWith 4 others
  11. 2011

    2 rounds

  12. Dec
    Cerulean PharmaSeries D · US · finsmes.com$15MWith 4 others
  13. Jun
    Nimbus TherapeuticsSeries A · US · xconomy.com$24MWith 2 others
  14. 2010

    4 rounds

  15. Nov
    Sutro BiopharmaSeries C · US · finsmes.com$37MWith 4 others
  16. Nov
    Cerulean PharmaSeries C · US · finsmes.com$24MWith 4 others
  17. Sept
    Cylene PharmaceuticalsSeries D · US · socaltech.com$12MWith 6 others
  18. Apr
    HemaQuest PharmaceuticalsSeries B · US · fiercebiotech.com$12MWith 3 others
  19. 2009

    8 rounds

  20. Dec
    FORMA TherapeuticsSeries B · US · masshightech.com$3.0MWith 3 others
  21. Dec
    FORMA TherapeuticsSeries B · US · altassets.com$26MWith 3 others
  22. Nov
    ReceptosSeries A · US · fiercebiotech.com$25MWith 3 others
  23. Nov
    Trinity BiosystemsDebt · US · deals.venturebeat.com$7.5MWith 4 others
  24. Jul
    Viamet PharmaceuticalsSeries B · US · sec.gov$25MWith 6 others
  25. Jun
    Aileron TherapeuticsSeries D · US · zibb.com$40MWith 6 others
  26. May
    Avid RadiopharmaceuticalsSeries D · US · avidrp.com$35MWith 7 others
  27. Jan
    Intradigm CorporationSeries B · US · fiercebiotech.com$21MWith 7 others
  28. 2007

    3 rounds

  29. May
    Avid RadiopharmaceuticalsSeries C · US · avidrp.com$26MWith 5 others
  30. Jan
    Cylene PharmaceuticalsSeries C · US · rctech.com$44MWith 7 others
  31. Jan
    FluidigmSeries E · US · deals.venturebeat.com$17MWith 9 others
  32. 2006

    4 rounds

  33. Sept
    Protagonist TherapeuticsSeries A · AU · protagonist-inc.com$9.0MWith 2 others
  34. Apr
    MedManage SystemsSeries D · US · biospacejobs.com$11MWith 3 others
  35. Feb
    InnoCentiveSeries A · US · innocentive.com$9.0MWith 2 others
  36. Jan
    Avid RadiopharmaceuticalsSeries A · US · avidrp.com$8.9MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 4 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

What the register says

From the firm's own filings with the SEC, which it must file accurately by law

1+funds on filenumbered funds in its name

Exits from the portfolio

Companies it backed that were later bought or listed4 in all

ReceptosBought by Celgene$7.3BJul 2015
Avid RadiopharmaceuticalsBought by Eli Lilly$800MNov 2010
Intradigm CorporationBought by Silence TherapeuticsUndisclosedDec 2009
MedManage SystemsBought by Physicians InteractiveUndisclosedApr 2009

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Lilly Ventures. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Lilly Ventures put money into.

Quick answers about Lilly Ventures

What does Lilly Ventures invest in?

Lilly Ventures invests most often at Series B and Series D (50% of the rounds on record), in sectors such as Health Care, Health Diagnostics and Impact Investing.

How active is Lilly Ventures?

28 investments on record, 0 of them in the last 12 months. The most recent was in Oct 2025.

What has Lilly Ventures invested in recently?

Its most recent investments on record: NewLimit (Oct 2025).

How big are Lilly Ventures's cheques?

The median round it joins is $45M.

Does Lilly Ventures lead rounds?

Rarely, if at all: none of its 28 investments on record names it as the lead.

Where does Lilly Ventures invest?

Most of the companies it backs are in the United States (93%) and Australia (7%).

Is Lilly Ventures investing now?

No investments in the last 12 months; the latest was in Oct 2025.

Who does Lilly Ventures invest alongside?

Most often Novartis Venture Fund (8 rounds together), SR One (5 rounds together) and Alta Partners (4 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it